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The EpiPen Problem: Analyzing Unethical 
Drug Price Increases and the Need for 
Greater Government Regulation 
Talal Rashid* 
In recent years, some pharmaceutical companies have started 
increasing the price of their existing drugs to exorbitant levels. 
Often, these drugs are medically necessary for patients, who are 
left to take on the high costs of the medicine. One recent example 
is Mylan, who raised the price of the EpiPen by four hundred 
percent, solely for the profit of its own company and to the 
detriment of consumers who rely on the EpiPen. Similar patterns 
of drug price increases have occurred in the past and will likely 
happen again in the future. This Comment will seek to identify the 
common elements of this pattern of increasing drug prices by 
looking at the behavior of corporations like Mylan and the way 
they operate, and it will assess current approaches to resolving 
this issue by looking at the roles of Congress, the Food and Drug 
Administration (FDA), and the Federal Trade Commission (FTC). 
The area of concern—apart from the way patients suffer from 
drug price increases—is that even after these companies are 
subjected to Congressional hearings to address their increasing 
drug prices, receive hefty fines from the FTC, experience bad 
press, and draw criticism about the issue of increasing drug 
prices, little change is made to resolve this problem. 
At the same time, industrialized nations around the world do not 
face the issue of increasing drug prices to the extent seen in the 
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United States. Three countries—Canada, Switzerland, and 
France—have protected their citizens by structuring their 
healthcare system in a way that gives pharmaceutical companies 
little room to raise drug prices to high levels. These countries 
utilize approaches such as implementing a price ceiling, 
negotiating with pharmaceutical companies by looking at a drug’s 
therapeutic value, and setting a reassessment standard to 
periodically check on pharmaceutical companies. To this end, this 
Comment will look at these approaches in more detail and will 
analyze how they can be applied to the United States’ own 
healthcare system in a way that would prevent pharmaceutical 
companies from raising the prices of their drugs to unethical 
levels and, ultimately, lower the cost of prescription drugs. 
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I. INTRODUCTION 
Picture this: Harry, a retired carpenter, has been taking the same drug 
for more than fifty years to treat his nerve disorder. Suddenly, the price of 
that drug is quadrupled overnight. Luckily, he is covered by Medicare, 
which will cover a portion of the cost that he takes every month. However, 
he will now have to pay three times his original monthly out of pocket cost 
for the drug. Meanwhile, across the country, Susan, a retired nurse, is 
dependent on a multiple sclerosis drug that she has been taking since the 
nineties. The company behind that drug has slowly been increasing the 
price of that drug over the years and Susan has managed to keep up with 
her out of pocket cost for the drug. However, this month the company has 
increased the price of the drug once again. Unfortunately, this time, Susan 
is no longer able to pay her share of the drug’s cost. She will have to go to 
her neurologist and seek a cheaper alternative, though it will not have as 
great of relief as the original drug. 
These scenarios represent the plight for many Americans: high drug 
price increases. Increasing prescription drug prices have been at the center 
of much debate for years now. There is no better example of this than the 
recent controversy involving the EpiPen. Mylan, the manufacturer behind 
the lifesaving EpiPen, was criticized nationally for raising the price of the 
drug by four hundred percent.1 Critics often argue that there is no need to 
increase the price of these drugs, while drug manufacturers go to great 
lengths to justify the price of their drugs. The discussion usually results in 
Congress confronting drug manufacturers about their high prices, drug 
manufacturers offering their own short–term solutions to avoid bad press, 
criticism of the policies of the Food and Drug Administration (FDA) and 
their part in handing over a monopoly to many of these companies, and 
the Federal Trade Commission fining some of these companies for 
anticompetitive behavior. However, all of this does very little to address 
the problem of drug price increases. In the end, the press forgets about the 
issue until the next public outcry. 
This Comment argues that a greater solution is needed to address this 
pattern of pharmaceutical drug price increases that is posing real problems. 
There is research that shows that the United States pays more for drugs 
than many other developed countries.2 Yet, critique of increasing 
prescription drug prices rarely focuses on what these other countries are 
                                                                                                             
1 Emily Willingham, Why Did Mylan Hike EpiPen Prices 400%? Because They Could, 
FORBES, http://www.forbes.com/sites/emilywillingham/2016/08/21/why-did-mylan-hike-
epipen-prices-400-because-they-could/ (last updated Aug. 22, 2016). 
2 See Robert Langreth, Blacki Migliozzi, & Ketaki Gokhale, The U.S. Pays a Lot More 
for Top Drugs Than Other Countries, BLOOMBERG (Dec. 18, 2015), https://www.
bloomberg.com/graphics/2015-drug-prices/. 
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doing and what sets them apart from the United States. For many of these 
countries, the government keeps drug prices in check by implementing a 
price ceiling, negotiating with drug manufacturers, and reassessing 
pharmaceutical companies after a certain time period to look at the cost–
effectiveness of their drug. Opponents of the approaches followed in these 
countries argue that this government intervention discourages drug 
manufacturers from engaging in research and development, which results 
in fewer drugs being developed.3 Although this is true to some extent, there 
are ways to adopt aspects of these systems to the United States that would 
avoid this criticism, while lowering the cost of prescription drugs. 
This Comment will focus on the issue of high pharmaceutical drug 
price increases by examining Mylan’s EpiPen price controversy and the 
actions of other pharmaceutical companies that have also taken part in 
price increases and seeks to identify the common elements of the issue, as 
well as provide a workable solution to this problem. Part II analyzes the 
behavior of the pharmaceutical companies and their role in the United 
States’ high drug costs. Part III looks at what is being done to address the 
issue by examining the role of Congress, the solutions that are being 
offered by pharmaceutical companies, the role of the FDA in handing over 
a monopoly to many of these companies, and the role of the FTC in 
curbing the harmful behavior of pharmaceutical companies that take part 
in anticompetitive behavior and increase the prices of their drugs. Finally, 
Part IV suggests a solution to high drug price increases by surveying 
government price control models of three developed nations—Canada, 
Switzerland, and France—and applies aspects of these models to the 
United States, while also addressing critics. 
II. THE BEHAVIOR OF THE CORPORATION 
Many pharmaceutical companies cite expensive research and 
developments costs as the reason behind high drug prices. These 
companies argue that because drug discovery can be so costly, they must 
raise drug prices to obtain increased profits and reimburse those costs.4 
Indeed, the cost to develop a new prescription drug that gains marketing 
                                                                                                             
3 See Kevin A. Hassett, Pharmaceutical Price Controls in OECD Countries, AM. 
ENTERPRISE INST. (Aug. 3, 2004), https://www.aei.org/publication/pharmaceutical-price-
controls-in-oecd-countries. 
4 Jeffrey Sachs, The Drug That Is Bankrupting America, THE HUFFINGTON POST, 
www.huffingtonpost.com/jeffrey-sachs/the-drug-that-is-bankrupt_b_6692340.html  
(last updated Apr. 18, 2015). 
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approval is around $2.6 billion.5 The high cost of research and 
development largely stems from factors such as large clinical trial sizes 
and a focus on chronic and degenerative diseases.6 
Yet, for some pharmaceutical companies, there is an increase in drug 
pricing, but no research and development cost to justify the price increase. 
In 2007, Mylan purchased a number of medicines from Merck KGaA, 
including the EpiPen auto injector.7 Today, the EpiPen, which has been 
around for decades and delivers $1 worth of the hormone epinephrine, has 
allowed Mylan to generate a profit of $1 billion per year.8 A detailed look 
at drug corporations, like Mylan, exposes the harmful behavior of these 
manufacturers, which ideally should give the federal government leverage 
in implementing meaningful changes. 
A. The Process of Raising Prices 
The path to increasing drug prices varies among pharmaceutical 
companies. For Mylan, that plan likely started in 2014, when it created a 
special, one–time stock grant that would allow its executives to be 
rewarded if Mylan’s earnings and stock price met specific goals by the end 
of 2018.9 According to health data and analytics company, Truven Health 
Analytics, Mylan began increasing the price of the EpiPen soon after 
introducing the special grant.10 Price increases for the company went from 
twenty–two percent annually to thirty–two percent for 2014 and 2015.11 
These figures translate to a price increase from $300 to $600 over a period 
of two years for a two–pack of the EpiPen.12 
For other companies, increasing drug prices is not a subtle process. In 
August 2015, Turing Pharmaceuticals acquired Daraprim, a drug used to 
treat potentially fatal parasitic infections, and increased the price from 
                                                                                                             
5 Henry G. Grabowski & Ronald W. Hansen, Cost to Develop and Win Marketing 
Approval For a New Drug Is $2.6 Billion, TUFTS CTR. FOR STUDY OF DRUG DEV. (Nov. 18, 
2014), http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study. 
6 Id. 
7 Cynthia Koons & Robert Langreth, How Marketing Turned the EpiPen Into a Billion–
Dollar Business, BLOOMBERG (Sept. 23, 2015, 10:00 AM), www.bloomberg.com/news/
articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business. 
8 Id. 
9 Gretchen Morgenson, EpiPen Price Rises Could Mean More Riches for Mylan 
Executives, N.Y. TIMES (Sept. 1, 2016), http://www.nytimes.com/2016/09/04/business/at-
mylan-lets-pretend-is-more-than-a-game.html. 
10 Id. 
11 Id. 
12 Daniel Kozarich, Mylan’s EpiPen Pricing Crossed Ethical Boundaries, FORTUNE 
(Sept. 27, 2016), http://fortune.com/2016/09/27/mylan-epipen-heather-bresch/. 
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$13.50 a tablet to $750.13 Similarly, Rodelis Therapeutics acquired 
Cycloserine, a drug that treats a highly resistant form of tuberculosis, and 
increased the price from $500 for 30 pills to $10,800.14 Valeant 
Pharmaceuticals was also criticized when it increased the price of 
Glumetza, a diabetes drug, from $572 to $3,432 and then increased it to 
$5,148 six weeks later.15 For these companies, acquiring drugs is part of 
an investment strategy of buying older drugs and then turning them into 
higher–priced specialty drugs.16 Critics, like the Infectious Diseases 
Society of America and HIV Medicine Association, have argued that these 
sudden price increases are unjustifiable for medically vulnerable patients 
in desperate need of these medications.17 
The pharmaceutical companies’ response to criticism has generally 
been to divert attention away from these practices. In an interview with 
CNBC, Mylan’s CEO Heather Bresch blamed the increasing price of the 
EpiPen on the health–care system and criticized it for requiring consumers 
to pay for both insurance premiums and out–of–pocket prescription 
medications that can sometimes reach full retail price.18 In her view, the 
system was never intended to make the consumers pay list price.19 Bresch 
also emphasized the costs Mylan faces, including the costs of 
manufacturing the product, distributing the product, and investing.20 Other 
companies like Valeant and Turing have had similar responses, focusing 
on distracting critics from the price increases by emphasizing patient 
assistance programs and research and development costs.21 
                                                                                                             
13 Andrew Pollack, Drug Goes From $13.50 a Tablet to $750, Overnight, N.Y. TIMES 
(Sept. 20, 2015), http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase
-in-a-drugs-price-raises-protests.html. 
14 Id. 
15 Gretchen Morgenson, How Valeant Cashed In Twice on Higher Drug Prices, N.Y. 
TIMES (July 29, 2016), http://www.nytimes.com/2016/07/31/business/how-valeant-cashed
-in-twice-on-higher-drug-prices.html. 
16 See Pollack, supra note 13. 
17 Id. 
18 Dan Mangan & Anita Balakrishnan, Mylan CEO Bresch: ‘No one’s more frustrated 
than me’ about EpiPen price furor, CNBC (Aug. 25, 2016), http://www.cnbc.com/2016/
08/25/mylan-expands-epipen-cost-cutting-programs-after-charges-of-price-gouging.html 
(last updated Aug. 25, 2016, 4:33 PM). 
19 Id. 
20 Id. 
21 See Linette Lopez, A murky part of Valeant’s business has suddenly caught everyone’s 
attention — and the company can’t be happy about it, BUSINESS INSIDER (Apr. 29, 2016), 
http://www.businessinsider.com/valeant-patient-assistance-programs-2016-4 (discussing 
Valeant’s patient assistance programs and critics questioning why Valeant didn’t just lower 
the prices of drugs that were too expensive for patients); see also Heather Long, Here’s 
what happened to AIDS drug that spiked 5,000%, CNN MONEY (Aug. 25, 2016), 
http://money.cnn.com/2016/08/25/news/economy/daraprim-aids-drug-high-price/index.
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As part of an investigation by Congress’ Committee on Oversight and 
Government Reform, documents revealed company strategies to deal with 
critics opposing price increases.22 For Valeant, the public relations strategy 
was to launch a new patient assistance program called the “Valeant 
Coverage Plus Program,” which was described as an “opportunity to 
expand patient access and utilization while maximizing value for niche 
brands.”23 The documents also detailed a public relations approach to 
increasing prices for orphan drugs—drugs treating rare conditions—and 
managing these price increases carefully to avoid negative press.24 Turing 
responded to negative press by reaching out to outside consultants, who 
suggested that Turing respond to critics by saying it is investing over sixty 
percent of its revenues into research and development.25 One consultant 
also suggested announcing a patient assistance program for patients who 
cannot access its drugs, which would force critics to shift their focus to the 
healthcare industry.26 
B. Moving Overseas 
In 2014, Mylan bought Abbott Laboratories’ generic drug 
manufacturing business for more than $5 billion.27 As a result of that deal, 
Mylan moved its headquarters to the Netherlands, which has a corporate 
tax of twenty percent, compared to the United States’ thirty–five percent 
statutory rate.28 Although this deal allowed Mylan to reduce its tax rate, 
nothing changed within the company—Mylan’s operational headquarters 
are still located in Pennsylvania, along with its main workforce.29 This 
                                                                                                             
html (“Turing has said it needs the profits on the drug in order to fund research and 
development of new drugs.”). 
22 See COMM. ON OVERSIGHT AND GOV’T REFORM, 114TH CONG., Documents Obtained 
by Comm. from Valeant Pharmaceuticals (2016), available at https://democrats-oversight.
house.gov/sites/democrats.oversight.house.gov/files/documents/Memo%20on%20Valean
t%20Documents0.pdf. 
23 Id. 
24 Id. 
25 COMM. ON OVERSIGHT AND GOV’T REFORM, 114TH CONG., Documents Obtained by 
Comm. from Turing Pharmaceuticals (2016), available at https://democrats-oversight.
house.gov/sites/democrats.oversight.house.gov/files/documents/Memo%20on%20Turing
%20Documents.pdf. 
26 Id. 
27 Renae Merle, EpiPen maker gave CEO more than $5 million to cover personal U.S. 
tax bill, WASH. POST. (Aug. 30, 2016), https://www.washingtonpost.com/news/wonk/wp/
2016/08/30/epipen-maker-gave-ceo-more-than-5-million-to-cover-personal-u-s-tax-
bill/?tid=a_inl. 
28 Id. 
29 Michael Hiltzik, Another reason to hate Mylan, which jacked up the price of life–
saving EpiPens: It’s a tax dodger, L.A. TIMES (Aug. 23, 2016, 10:45 AM), http://www.
latimes.com/business/hiltzik/la-fi-hiltzik-mylan-inversion-20160823-snap-story.html. 
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strategy is known as tax inversion, a phenomenon that has been around 
since the 1980s.30 
Through tax inversion, an independent U.S. company can create or 
buy a foreign parent company and escape the U.S. tax on worldwide 
income.31 This also allows companies to take advantage of interest 
deductions for their own affiliates abroad.32 Although Congress tried to 
crackdown on tax inversion in 2004, a loophole allowed companies, like 
Mylan, to adopt the tax address of foreign acquisitions.33 Tax inversion 
allows pharmaceutical companies to grow amid pressure from the 
government and insurance companies to control costs and compete with 
foreign rivals.34 Bresch argued that before the inversion, Mylan found it 
impossible to maintain competitiveness under U.S. tax rules and criticized 
the unleveled playing field in the country, which penalizes U.S.–based 
companies.35 
Tax inversion not only provided Mylan with a way to lower taxes, it 
was also a useful business strategy. When its shareholders approved the 
Abbott Laboratories acquisition, many overlooked an anti–takeover clause 
known as stichting.36 A stichting is a Dutch legal entity that has no 
shareholders but may acquire and dispose of assets, grant security, and 
provide guarantees.37 Through stichting, Dutch–listed corporations are 
allowed to have a separate class of voting shares that allow the holder to 
have a fixed dividend, with voting shares being given to a foundation 
established at the time the corporation goes public.38 
Mylan set up a stichting foundation comprised of a four–man board 
that would fight against threats to Mylan’s interests by having voting 
                                                                                                             
30 Zachary Mider, Tax Inversion, BLOOMBERG, https://www.bloomberg.com/quicktake/
tax-inversion (last updated Mar. 2, 2017, 9:35 PM UTC). 
31 Id. 
32 Id. 
33 Max Nisen, Big Pharma Murdered Tax Inversions, BLOOMBERG (Apr. 6, 2016 1:57 
PM), https://www.bloomberg.com/gadfly/articles/2016-04-06/big-pharma-ruined-tax-
inversions-for-everybody. 
34 Jonathan D. Rockoff, Why Pharma Is Flocking to Inversions, WALL ST. J. (July 14, 
2014, 1:53 PM), http://www.wsj.com/articles/why-pharma-is-flocking-to-inversions-1405
360384. 
35 See Hiltzik, supra note 29. 
36 Jen Wieczner, Why Wall Street loves to hate Mylan’s CEO, FORTUNE (Sept. 11, 2015), 
http://fortune.com/2015/09/11/mylan-ceo-heather-bresch/. 
37 Robert A. Profusek et al., Shedding Light on the Dutch “Stichting”: The Originals 
and Purpose of an Obscure but Potentially Potent Dutch Entity, JONES DAY (Feb. 2016), 
at 1, http://www.jonesday.com/files/Publication/f4c70f5c-c1b1-4c3b-8141-b515d8eb472c
/Presentation/PublicationAttachment/6f54fc41-e25d-404f-8420-5fdf6c80ad04/Shedding
%20Light%20on%20the%20Dutch%20Stichting.pdf. 
38 Id. at 2. 
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shares worth up to fifty percent of the company’s voting rights.39 This 
turned out to be useful when Mylan used the stichting to block Teva 
Pharmaceuticals’ $40 billion hostile takeover bid for the company, which 
would have been accepted by common shareholders.40 Shareholders—
who were in favor of the deal because it would give them a premium of as 
much as forty–eight percent over their shares’ value—were told that 
Mylan was a stakeholder company, not a shareholder company, and it 
would consider the interests of employees, patients, and investors.41 Two 
shareholders responded by filing lawsuits that claimed references to the 
anti–takeover clause in the Abbott Laboratories’ acquisition were vague 
and misleading.42 
Mylan was one of the last pharmaceutical companies to take advantage 
of tax inversion. These inversions caught the attention of the Obama 
administration, which proposed tougher regulations after Abbvie, a 
pharmaceutical company, tried to buy Ireland’s Shire Pharmaceuticals in 
2014.43 Similarly, U.S–based Pfizer Inc. and Ireland–based Allegan 
abandoned their $160 billion merger, which would have allowed Pfizer to 
cut its tax bill by an estimated $1 billion annually by moving its company 
to Ireland.44 As a result of the U.S. Department of Treasury’s new 
regulations, officials argue that tax inversions appear to be largely over.45 
C. Reaping the Benefits 
Since acquiring the EpiPen and raising its price, Bresch has seen a 
compensation increase from more than $2 million to nearly $19 million.46 
Similarly, other Mylan executives, including its president and chief 
commercial officer, have seen their pay increased.47 Mylan’s stock price 
also tripled, increasing from $13.29 in 2007 to a high of $47.59 in 2016.48 
                                                                                                             
39 See Wieczner, supra note 36. 
40 Id. 
41 Id. 
42 Id. 
43 See Nisen, supra note 33. 
44 Caroline Humer & Ankur Banerjee, Pfizer, Allergan scrap $160 billion deal after U.S. 
tax rule change, REUTERS (Apr. 6, 2016, 6:54 AM), www.reuters.com/article/us-allergan-
m-a-pfizer-idUSKCN0X3188. 
45 Kristen Hallam, Cynthia Koons and Zachary Tracer, Pfizer, Allergan $160 Billion 
Merger Killed by U.S. Tax Rules, BLOOMBERG (Apr. 6, 2016), http://www.
bloomberg.com/news/articles/2016-04-06/pfizer-allergan-end-160-billion-merger-amid-
new-tax-rules (Membership to Bloomberg BNA is required to view archival articles). 
46 Ben Popken, Mylan CEO’s Pay Rose Over 600 Percent as EpiPen Price Rose 400 
Percent, NBC NEWS (Aug. 23, 2016), http://www.nbcnews.com/business/consumer/
mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591. 
47 Id. 
48 Id. 
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Gilead Sciences is another company that profited immensely when it 
introduced expensive life–saving Hepatitis C medications, such as 
Sovaldi.49 Sovaldi costs $84,000 for a twelve–week treatment, while the 
manufacturing cost was between $100 to $1,400.50 As a result of the 
increasing costs, Gilead’s CEO, John C. Martin, saw his compensation 
grow from $32.5 million in 2006 to $192.8 million in 2014.51 
Other pharmaceutical companies, like Valeant, make profit from price 
increases through price appreciation credits. Drug companies use these 
credits to raise the cost wholesalers have to pay for a product that they are 
contracted to distribute.52 Under these price appreciation credits, when 
Valeant raised the price of a drug, it would receive a credit from 
wholesalers that reflected the impact of those price increases on the 
wholesalers’ inventory.53 In its fourth quarter for 2015, these credits made 
up twenty–five percent, or $138 million, of its $562 million operating cash 
flow.54 According to Adam J. Fein, President of Pembroke Consulting and 
author of the Drug Channels blog, these credits guaranteed Valeant that it 
would retain profit from price increases.55 
D. The Role of Advocacy Groups Who Speak for Patients 
While pharmaceutical companies have continued to raise drug prices, 
patient advocacy groups have remained silent about the issue. Patient 
advocacy groups are organizations that provide patient and caregiver–
related education, advocacy, and support services.56 These groups play an 
important role in educating the public and lobbying the government to 
increase funding for research and treatment, as well as advocating for 
legislative changes for their target diseases.57 By holding great influence 
                                                                                                             
49 William Rice and Frank Clemente, Gilead Sciences: Price Gouger, Tax Dodger, 
AMERICANS FOR TAX FAIRNESS (July 2016), https://americansfortaxfairness.org/new-
report-taxpayer-supported-gilead-sciences-is-price-gouging-the-public-then-dodging-
taxes-on-the-huge-profits/ (follow “investigative report” in the first sentence of the news 
report for full document). 
50 Id. 
51 Id. 
52 See Morgenson, supra note 9. 
53 Id. 
54 Id. 
55 Id. 
56 Susannah L. Rose, Patient Advocacy Organizations: Institutional Conflicts of 
Interest, Trust, and Trustworthiness, J.L. MED. ETHICS 680, 680 (2013), https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC4107906/ (follow hyperlink next to “doi” at the 
top of the HHS Public Access page to reach properly paginated PDF). 
57 Katie Thomas, Furor Over Drug Prices Puts Patient Advocacy Groups in Bind, N.Y. 
TIMES (Sept. 26, 2016), http://www.nytimes.com/2016/09/28/business/furor-over-drug-
prices-puts-patient-advocacy-groups-in-bind.html. 
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in Washington DC and having multimillion–dollar budgets, these groups 
have all the necessary tools to make a positive impact on drug pricing.58 
Critics argue that because patient advocacy groups are funded by the 
same pharmaceutical companies that increase drug prices, there is a 
conflict of interest.59 For example, the Leukemia and Lymphoma Society 
receives $50 million a year from drug makers, which makes up sixteen 
percent of their funding.60 Other groups receive up to twenty–percent of 
their revenue from drug funding.61 In exchange for these donations, the 
patient groups help drug companies by signing up participants for clinical 
trials, running financial assistance programs, and lobbying Congress to 
approve drugs or implement favorable legislation.62 
For these patient advocacy groups, their discussion with 
pharmaceutical companies has largely been limited to asking for better 
treatments or focusing price discussion on insurance companies.63 When 
certain groups have proposed to review even modest plans to combat drug 
prices, they have been met with resistance from other patient groups, 
members of Congress, as well as pharmaceutical companies that donate to 
their group.64 As a result, most remain silent on the issue. Critics have 
suggested that these patient advocacy groups must limit the relationship 
between fundraisers and policymakers and fully disclose financial 
relationships.65 Otherwise, they risk losing their independence and, more 
importantly, the public’s trust.66 
III. CURRENT APPROACHES TO REMEDYING DRUG PRICE INCREASES 
A. The Role of Congress 
Congress has responded to the public outcry about high drug prices by 
confronting pharmaceutical companies. In 2015, Democratic members of 
the House Committee on Oversight and Government Reform launched an 
Affordable Drug Pricing Task Force to address pharmaceutical companies 
                                                                                                             
58 Id. 
59 Id. 
60 Jayne O’Donnell, Patient groups funded by drugmakers are largely mum on high drug 
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and their pricing strategies.67 Spearheaded by Representative Elijah 
Cummings (D–MD), these Task Force members have sought to 
understand why companies increase their drug prices so quickly and with 
little transparency as to why these drugs have such a high cost.68 Similarly, 
the Senate Special Committee on Aging has also held hearings regarding 
the sudden increasing prices of medicines that have been on the market for 
years.69 
The response from companies has varied. In early 2016, the House 
Committee on Oversight and Government Reform held a hearing with 
Valeant Pharmaceuticals, where Committee members accused the 
company of ruining the reputation of the pharmaceutical industry.70 In 
turn, the company admitted that it bought off–patent medications that had 
no generic competition and raised the prices for maximum profit.71 
Valeant’s interim CEO Howard Schiller assured the Committee that the 
company would be abandoning that method.72 
Later that year, the Committee held a hearing with Heather Bresch 
after news of Mylan’s aggressive EpiPen pricing strategy came into the 
public eye.73 At the hearing, Committee members questioned Bresch about 
Mylan’s EpiPen price increases, as well as her pay and other company 
practices.74 Bresch responded by defending her company and emphasized 
that it has expanded access to EpiPens by distributing them for free at 
schools. In her words, Mylan has found a balance between price and access 
to the EpiPen.75 As a result of that hearing, Mylan made two promises: to 
extend EpiPen’s shelf life from 18 months to two years and to introduce a 
$300 generic version of its product.76 
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Mylan’s promises are, in fact, not very promising. An extension of the 
shelf life of the EpiPen still has no effect on the high cost of the drug. 
Furthermore, although a $300 generic EpiPen two–pack sounds like a step 
in the right direction, this price is still three times the cost of the drug when 
Mylan acquired its rights in 2007.77 As for Valeant, it has still been making 
headlines for raising its drug prices, although the company claims the price 
hikes are no longer as significant as they were in the past. Last October, 
the company raised the prices of several drugs from two to nine–percent 
of their original price, which Valeant argued was part of their commitment 
to keep drug prices affordable.78 However, that same month, the company 
was also criticized for raising the price of a lead poisoning treatment from 
a price of $950, at the time it was acquired by Valeant in 2013, to 
$27,000.79 Analysts have argued that these price increases lead them to 
believe that Valeant still relies on price increases to boost revenue 
streams.80 
The outcomes of these House Committee hearings highlight how little 
help they are in solving the problem of rising drug prices. In addition, these 
hearings have not resulted in any legislation that addresses the issue of 
drug price increases. Critics have argued that Committee members have 
little understanding of drug markets and fail to understand the bigger issue 
of overall drug costs.81 According to Ameet Sarpatwari, an instructor at 
Harvard Medical School, these hearings only serve as a way to release 
public frustration and fail to institute meaningful systemic reform.82 
B. Solutions Offered by Pharmaceutical Companies 
In response to public scrutiny, pharmaceutical companies have taken 
it upon themselves to offer their own solutions. Following backlash over 
its price of the EpiPen, Mylan said it would offer instant savings cards 
worth $300 to patients who pay full price for the drug out of pocket.83 This 
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would reduce the price by fifty percent for these patients who have no 
insurance or those who have a high deductible.84 The company also said it 
would offer financial assistance to low–income families that would allow 
them to receive the EpiPen two–pack for free.85 
However, critics have argued that this is simply a public relations fix 
that fails to address the high price of the drug. According to them, the 
savings cards would only be used by a fraction of the people who use the 
EpiPen.86 Furthermore, the high cost of the drug would still be paid by the 
insurer, which is subsequently reflected in higher premiums.87 The savings 
cards also cannot be used by people without insurance or those enrolled in 
government–funded health programs, like Medicaid.88 America’s Health 
Insurance Plans, the leading health insurance lobbying group, said this 
tactic of implementing patient assistance programs and co–pay support has 
been used by pharmaceutical companies in the past in an attempt to cover 
price hikes.89 
This exact strategy was used in the past by Valeant Pharmaceuticals 
when it was in the public eye after its price increases. In 2015, Valeant 
struck a deal with Walgreens to distribute thirty of its products at generic 
prices, reducing their prices from five to ninety–five percent.90 However, 
the next year, the company began charging those patients a co–pay of $35 
on certain drugs.91 Opponents of this strategy argued that Valeant was 
refusing to lower drug prices and was the same company in a new 
disguise.92 Similarly, Mylan’s solution of creating a savings card and a 
financial assistance program does little to help the problem of an expensive 
EpiPen. Unfortunately, these approaches only put a temporary band–aid 
on the issue without seeking to fix the underlying issues. 
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C. The Role of the Food and Drug Administration 
In 1984, Congress passed the Hatch–Waxman Act, which governs 
today’s generic drug approval process.93 The Hatch–Waxman Act was 
intended to accomplish two goals.94 The first goal was to encourage the 
development of new drugs by allowing innovator drug manufacturers to 
have patent protection and market exclusivity for a certain time period, 
allowing them to regain their investment in the development of the drug.95 
Second, Congress wanted to make sure that, once that patent protection 
and market exclusivity period was over, consumers were able to access 
less expensive, generic versions of those innovator drugs.96 
The latter goal has become the subject of much debate, with critics 
arguing that the Food and Drug Administration (FDA) has not done its job 
in assuring that generic drugs are reaching the market in an efficient 
manner.97 There is no better example of this than the EpiPen, which is an 
off–patent drug with no generic competitor.98 According to a report by the 
Kaiser Family Foundation, as of July 1st 2016, the FDA had 4,036 generic 
drug applications awaiting approval, with the average approval time being 
forty–seven months.99 However, the FDA’s approval process is not a new 
problem.100 Beginning in 2012, the FDA’s generic backlog became such a 
big issue that the government began charging user fees to generic 
manufacturers to provide funds to speed up the process.101 As a result of 
these resources, the FDA moved the Office of Generic Drugs to the FDA’s 
main campus, hired an additional 1,000 employees, and replaced the 
office’s information technology system.102 The FDA argues that this will 
allow it to reduce the backlog of pending applications and the time 
required to review generic drug applications for safety.103 
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Nonetheless, critics are skeptical about whether these changes will 
truly result in a faster approval time for generics. Last year, U.S Senator 
Tom Cotton (R–Ark) wrote a letter to the FDA to complain about there 
being a decrease in approvals, but an increase in the time it takes the 
agency to review applications.104 Similarly, the Association for Accessible 
Medicines, which educates policymakers about the role of generics in the 
healthcare system,105 has said it is cautious about whether there will be an 
improvement and will wait to see if the FDA’s actions translate to more 
generics being approved.106 
As for the EpiPen, there is some hope that it will face generic 
competition in the future, with Teva Pharmaceuticals due to release a 
generic version of the drug by late 2017 or early 2018.107 Previously in 
2016, Teva’s application for a generic version of the EpiPen was rejected 
by the FDA due to “certain major deficiencies.” The FDA’s delay in 
bringing Teva’s generic EpiPen to the market allowed Mylan to avoid a 
large decline in sales.108 The effect that a generic EpiPen will have on the 
price of Mylan’s EpiPen remains to be seen. For now, one thing is for 
certain—the FDA has done a disservice to consumers by failing to 
introduce few, if any, generic competitors into the market for drugs like 
the EpiPen. Since many of these branded drugs have little generic 
competition,109 the pharmaceutical companies behind these drugs don’t 
have much of an incentive to reduce the cost of these drugs. As a result, 
the FDA has essentially handed over a monopoly to these pharmaceutical 
companies, who control that specific drug’s market and are left to their 
free will to raise prices. 
D. The Role of the Federal Trade Commission 
The Federal Trade Commission (FTC) is another governmental 
agency that has a significant role in addressing increasing drug prices. The 
goal of the FTC is to protect customers against business practices that are 
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anticompetitive, to allow consumers to have knowledge about the 
competitive practices between corporations, and to allow consumers to 
have a choice between products.110 When it comes to drug price increases, 
the FTC does not have any power to force a manufacturer to regulate its 
drug prices.111 However, the FTC can protect consumers when a price 
increase is the result of anticompetitive behavior.112 For example, if there 
is an illegal anticompetitive agreement between drug manufacturers to 
increase prices or exclude a drug manufacturer from competing in the 
market, then the FTC can step in and penalize those who are taking part in 
the illegal activity.113 
One recent example of the FTC’s authority in the pharmaceutical 
sector is the case of Mallinckrodt, an Ireland–based drug manufacturer. In 
2017, Mallinckrodt had to pay a $100 million settlement with the FTC 
after the agency concluded that Questcor, a subsidiary of the drug maker, 
monopolized a drug and then raised its price.114 According to the FTC, 
Questcor was a major seller of a treatment for infantile spasms and 
multiple sclerosis and purchased the U.S. rights to a rival medicine from 
another pharmaceutical company.115 Consequently, Questcor no longer 
had competitors for its own medicine.116 As a result of its market control, 
Questcor began raising the price of its drug and this resulted in close to $1 
billion in annual sales.117 Mallinckrodt then acquired Questcor and 
continued to increase the price of the drug.118 Eventually, this caught the 
attention of the FTC, who fined Mallinckrodt $100 million for maintaining 
the monopoly.119 Furthermore, the FTC required Mallinckrodt to sell off 
the U.S. rights to the competing drug that Questcor had bought.120 
Based on the FTC’s handling of the Mallinckrodt case, the FTC seems 
to be an important figure in the discussion of increasing drug prices. The 
FTC’s ability to monitor drug companies and penalize those who take part 
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in anticompetitive behavior is a useful resource to have when 
manufacturers take part in this illegal activity. At the same time, the fact 
that the FTC’s role is limited to overseeing anticompetitive behavior 
means that the agency alone is not enough to curb drug price increases. 
There has been discussion that although the FTC is able to obtain large 
settlements, these settlements pale in comparison to the profit made by the 
drug manufacturer.121 For example, Mallinckrodt was faced with a $100 
million fine for monopolizing a drug that brought in one third of its $3.4 
billion net sales in 2016.122 Since these fines are not a huge loss for the 
manufacturer, the company often repeats the illegal behavior and many of 
them have been repeat offenders of anticompetitive behavior.123 
A testament to these critics’ concerns is Mylan itself. In 2000, the FTC 
found that Mylan had agreed to exclusive supply contracts with three 
suppliers of an ingredient used in manufacturing two anti–anxiety drugs.124 
The exclusive supply contracts prevented Mylan’s competitors from 
obtaining the ingredients necessary to make the drugs.125 Following this, 
Mylan obtained market exclusivity and began raising the price of its own 
anti–anxiety drugs.126 As a result of this anticompetitive behavior, the FTC 
sued Mylan and the three suppliers, resulting in a $100 million 
settlement.127 In 2017, the FTC again opened a preliminary investigation 
into Mylan after suspecting that the company violated antitrust laws by 
making minor changes to the EpiPen, which prevented lower–priced 
competitors from entering the market.128 The FTC is concerned about 
whether Mylan extended its patent by changing dosage levels and if the 
company entered into any agreements to delay market introduction of 
cheaper versions of the EpiPen.129 The results of the FDA’s preliminary 
investigation, however, remain to be seen.130 
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IV. A SOLUTION IN GOVERNMENT PRICE CONTROL 
The increasing cost of drugs such as the EpiPen speaks to the bigger 
issue of whether consumers should be willing to accept any price these 
pharmaceutical companies present to them. According to a study 
performed by researchers from Harvard Medical School, in 2013, per 
capita spending on prescription drugs in the United States was higher than 
nineteen other industrialized nations.131 Statistics such as this emphasize 
how important it is to look at the healthcare systems of other countries and 
see what they are doing differently. An analysis of the approaches taken 
in three industrialized nations—Canada, Switzerland, and France—
reveals that the governments of these countries have a greater role in 
regulating drug prices by negotiating prices with pharmaceutical 
companies, as well setting price ceilings to prevent companies from raising 
prices to egregious levels. More importantly, although these countries 
have healthcare systems that are different from the United States’—one 
example being universal healthcare—many aspects of the approaches 
taken by these countries can still be implemented in the U.S. 
A. Models in Foreign Countries 
1. Canada 
In Canada, drug prices are monitored by the Patented Medicine Prices 
Review Board (PMPRB).132 Created in 1987, the PMPRB acts as an 
independent, quasi–judicial body that enforces sanctions and price 
reductions for patented pharmaceutical products.133 The PMPRB limits its 
power to regulating the price of patented drugs during the duration of their 
patent time period.134 The Board makes sure that drug prices are not 
excessive by comparing the price of the drug to the prices of existing drugs 
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in Canada or to prices in seven of the world’s dominant markets, such as 
France, Switzerland, the United Kingdom, and the United States.135 Under 
the Board’s existing rules, the cost of a patented drug cannot exceed the 
highest price of the same drug in the seven countries.136 
As for new drugs, the Board assesses the price of these drugs by using 
a three–tiered scale that evaluates the degree of innovation.137 Under the 
first category, drugs that are a new dosage or form of an existing medicine 
are considered to have an excessive price if the price does not have a 
reasonable relationship to the average price of that medicine in similar 
dosage forms.138 Under the second category, drugs that are considered to 
be a breakthrough or a big improvement over similar existing medicines 
are excessive if the price is higher than that of comparable products in its 
therapeutic class and the international median price of that medicine.139 
Under the final category, drugs that provide little to moderate therapeutic 
advantage over similar medicines are considered to have an excessive 
price if the price is higher than similar products in the Canadian market or 
that drug’s international median price.140 
By regulating prices through an agency like PMPRB, Canada has been 
able to lower its drug prices closer to median international prices.141 For 
example, in 1987, Canadian prices for patented medicines were higher 
than the international median price by more than twenty–percent.142 
Following the creation of the PMPRB, the prices began to decrease in the 
early nineties and eventually stabilized to ten–percent below the median 
price in seven comparable countries.143 Finally, in 2005, the prices of drugs 
were eight–percent lower than the median price of seven comparable 
countries.144 
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2. Switzerland 
In Switzerland, the population is covered by a universal basic health 
insurance plan that includes drug coverage.145 Drug coverage under the 
basic health insurance plan is limited to pharmaceuticals that have gone 
through an assessment process and are included in a Specialty List.146 The 
Federal Office of Public Health (FOPH) regulates the inclusion of these 
drugs in the Switzerland’s universal health insurance plan and oversees 
the price of covered drugs, whether on or off–patent.147 A drug is covered 
if it’s approved by Swissmedic (Switzerland’s equivalent of the FDA), 
considered effective and appropriate, and has value–for–money.148 
When determining value–for–money, the FOPH compares at the 
manufacturer’s proposed price to the manufacturer’s set price abroad, the 
drug’s therapeutic value compared to other similar medications, and the 
drug’s daily cost or cost per cure compared to similar medications.149 If 
the drug produces a therapeutic effect at the lowest possible cost, it is 
determined to be value–for–money.150 Similar factors are looked at when 
the OFSP establishes a maximum price for newly listed drugs, including 
the price of the drug in foreign countries, such as Germany and the United 
Kingdom, the effectiveness of the new drug, and research and 
development costs.151 This same assessment is performed after the patent 
for the drug expires.152 
As a result of its price regulation, there is now a smaller gap between 
the price of drugs in Switzerland and other European countries.153 At the 
same time, studies also show that the cost of Swiss drugs is still greater 
than other European countries because the prices of drugs are either set 
higher in Switzerland or the prices decrease in other countries after the 
drug launches in Switzerland.154 Nonetheless, after the regulation of drug 
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prices in the late nineties, Swiss drug prices are no longer significantly 
higher than other comparable countries.155 
3. France 
In France, the general population is also covered by universal health 
insurance.156 The country follows a step–by–step process for covering 
prescription medicines and setting their price.157 Following approval to be 
sold in the market, the drug is then evaluated by the Transparency 
Committee, which assesses the therapeutic value of the drug and compares 
it with existing drugs.158 When assessing the therapeutic value of the drug, 
the Transparency Committee categorizes the drug into five categories: 
major improvement, significant improvement, moderate improvement, 
minor improvement, and no improvement.159 The Committee is also free 
to re–evaluate the drug every five years or earlier.160 When determining a 
drug’s category, the Committee looks at factors such as the drug’s 
effectiveness and possible side effectives, its medical benefit, seriousness 
of the condition it is treating, its preventative or symptomatic properties 
and its impact on the public’s health.161 
After the Committee evaluates the therapeutic value, the Health 
Product Pricing Committee then negotiates the price of the drug with the 
manufacturer and forms a contract that includes rebates and price re–
evaluations.162 The system of categorizing drugs directly impacts the level 
of co–payment and the price negotiations, which depend on a drug’s 
effectiveness.163 For example, the reimbursement rates for drugs range 
from thirty–five percent to sixty–five percent.164 As a result, a drug that 
falls into one of the first three categories is likely to have a higher 
reimbursement rate than a drug in the fourth or fifth category.165 The 
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remaining cost is covered for most French citizens, who have 
complementary health insurance.166 
The Pricing Committee also sets a maximum price ceiling for 
medicines that are used for outpatient care and expensive hospital 
medicines, with innovative drugs being compared with prices in similar 
countries.167 For these reasons, the final price of a drug is subject to various 
factors, including the category it is placed in and the price in similar 
countries.168 Furthermore, the contract between the drug manufacturer and 
the Pricing Committee also includes a payback procedure.169 The 
country’s parliament approves a budget for the public health insurance 
system and defines a rate for its pharmaceutical expenditure.170 When the 
pharmaceutical expenditure exceeds that rate, the drug manufacturer must 
offset that cost through a rebate.171 These rebates are based on, among 
other factors, how innovative each company’s product is and its share of 
the increase in expenditure.172 
Finally, due to legislation that places importance on cost–effectiveness 
data, manufacturers are sometimes required to produce additional data 
after a certain time period.173 This data is used to reassess the drug’s 
therapeutic value by looking at the drug’s added value related to 
effectiveness, which is based on the standard used by the Transparency 
Committee in categorizing drugs.174 This reassessment can result in price 
changes, such as a reduction in the reimbursement rates for companies.175 
However, innovative drugs that fall within the first three categories and 
offer a significant improvement receive the benefit of having a stable price 
for five years.176 Overall, as a result of its regulation of drug prices, France 
has been able to maintain drug prices at a lower level than comparable 
countries, like Germany, Spain, and the United Kingdom.177 
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B. Applying these Methods to the United States 
1. Setting a Price Ceiling for Off–Patent Medications 
One of the main complaints in the discussion of pharmaceutical drug 
pricing is the increase in the price of drugs that have been on the market 
for years.178 Often, the list price for many of these existing drugs rises ten 
percent or more year after year.179 One solution to this problem would be 
for the United States to set up an independent board, as seen in Canada, 
which would monitor the prices of off–patent medications. In Canada, the 
PMPRB monitors the price of patent medications by comparing them to 
seven of the world’s most industrialized nations.180 Similarly, the United 
States should monitor the prices of off–patent drugs by comparing the 
prices of these drugs to those in seven countries that have dominant 
markets like the U.S. Under this system, the U.S. would prevent drug 
manufacturers from raising the price of an off–patent drug higher than the 
highest price of a comparable drug in any of the seven countries. Since the 
United States ranks as paying the highest cost for drugs in the world, with 
the difference being substantial, this system could lead to significant 
changes.181 By implementing such a board, drug manufacturers of 
medications would no longer be able to raise prices to high levels. 
Critics of a price control structure argue that a system that regulates 
the price of patented drugs impedes innovation by discouraging research 
and development of new medications.182 A report by the U.S. Department 
of Commerce concluded that countries that set price controls on new drugs 
reduce company compensation to levels closer to direct production costs, 
leaving less revenue for research and development.183 As a result, a 
reduction in research and development impedes health benefits for the 
citizens of those countries.184 Furthermore, another study concluded that if 
countries with price controls on patented drugs were to remove those 
regulations, research and development expenditure would increase from 
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$17 billion to $22 billion.185 In turn, this would result in newer drugs being 
developed.186 
However, the price ceiling system that is being argued for in this 
Comment is different from those seen in other countries, like Canada. 
Under the United States’ price ceiling, the independent board would not 
set a price ceiling for patented drugs. As stated earlier in this Comment, 
under the Hatch–Waxman Act, innovator drug manufacturers are given a 
patent exclusivity period to regain their research and development costs.187 
For these reasons, a price control system in the U.S would focus 
exclusively on off–patent medications. The idea behind this is that if a 
medication is off–patent, it is past its patent exclusivity period. As a result, 
the manufacturer of that drug has regained much its research and 
development cost during the exclusivity period. By only regulating the 
price of the drug once it is no longer patent–protected, this would satisfy 
critics who argue that these price controls discourage the development of 
newer drugs by reducing a manufacturer’s overall revenue. 
Many of the drugs that have been subjected to high price increases are 
those that have expired patents.188 By implementing a price control 
through the creation of an independent board, like the PMPRB, the United 
States would reduce the price of off–patent drugs and prevent companies 
from marking up drugs that have been on the market for years. As seen in 
Canada, regulation of patented drugs has allowed prices to stabilize below 
the median price in comparable countries. If the U.S. were to follow the 
same system, but only for off–patent medications, like the EpiPen, there 
would likely be a similar result here. 
2. Increasing the Negotiation Power of the Government 
One of the other areas of conflict in the conversation about drug price 
increases is the need for an expansion in the U.S. government’s ability to 
negotiate drug prices with manufacturers. Currently, Medicaid is able to 
negotiate drug prices with manufacturers directly through the Medicaid 
Drug Rebate Program.189 Under this program, manufacturers enter into 
rebate agreements with the Secretary of the Department of Health and 
Human Services and pay a rebate when a drug is paid for under a state 
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plan.190 The amount of the rebate is determined by factors such as whether 
it is an innovator drug, non–innovator drug, or a drug that is a new 
formulation of a brand name drug, among others.191 For example, an 
innovator drug manufacturer has to provide a minimum rebate of 23.1% 
of the average price that the manufacturer receives for sale per unit.192 As 
for Medicare Part D, which covers prescription drug coverage, Congress 
has prohibited the government from negotiating drug prices for Medicare 
beneficiaries.193 Instead, this negotiating power is given to private insurers 
that have a contract with Medicare, who also obtain rebates.194 
One way to address increasing drug prices would be for Congress to 
repeal part of the Medicare Modernization Act, which prohibits the 
government from negotiating drug prices for Medicare Part D 
beneficiaries.195 The Congressional Budget Office (CBO) has argued that 
if the federal government were to negotiate lower prices for Medicare 
beneficiaries, it would have a harmful effect on federal spending.196 The 
CBO based this conclusion on its understanding that the government 
would not be able to obtain greater discounts than those obtained by the 
private plans that have a contract with Medicare.197 Furthermore, the CBO 
has argued that private plans compete for beneficiaries based on cost and 
coverage, which means they face the risk of paying for costs that exceed 
their projections.198 Other opponents have a similar view, arguing that the 
government would not be able to obtain greater discounts than the private 
plans already do.199 
However, there has been great support for allowing the government to 
negotiate drug prices for Part D beneficiaries. Proponents of this plan 
argue that if the government was able to negotiate drug prices on behalf of 
Medicare Part D beneficiaries, it would obtain deeper discounts.200 These 
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proponents argue that discounts would be especially beneficial for high–
priced drugs that have no competition, which includes many of the drugs 
that have seen high price increases.201 These supporters are correct and the 
federal government should be allowed to negotiate drug prices for 
Medicare Part D and obtain the same rebates that are obtained through 
Medicaid. For example, the rebates obtained by Medicare reduce spending 
on drugs by nineteen percent, while the rebates obtained by Medicaid 
reduce spending by forty–five percent.202 By negotiating on behalf of 
Medicare Part D beneficiaries, as does Medicaid, the government could 
likely be able to reduce spending on drugs. 
Furthermore, under Medicaid, drug companies must pay a greater 
rebate if the price of their drug rises faster than the general inflation.203 
Since many of these drug prices do end up rising faster than general 
inflation, these rebates account for more than half of the rebates paid to 
Medicaid.204 A similar negotiation under Medicare Part D would expand 
these discounts to an additional group consisting of 30 million older 
Americans and individuals with disabilities.205 
Critics of high drug prices also complain about the lack of 
transparency when it comes to drug price increases.206 Many of these 
critics argue that the federal government should have access to the 
information that the manufacturer believes justifies the high cost.207 
Transparency for newly introduced drugs includes payments 
manufacturers make to doctors for research, meals and entertainment, and 
consulting and giving promotional speeches.208 In addition, manufacturers 
have had to disclose the results of their clinical trials.209 
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States have also taken it upon themselves to address drug price 
increases and the lack of transparency. In 2016, Vermont was the first state 
to require drug manufacturers to give an explanation for large price 
increases.210 The state requires officials to identify drugs that saw price 
increases of at least fifteen–percent in the previous year and over fifty–
percent over the last five years.211 Following this assessment, the state 
requires Vermont’s attorney general to reach out to drug manufacturers 
and seek explanations for the increases.212 As of now, the law is limited to 
transparency and doesn’t give Vermont the power to cap prices that are 
excessive, but the state is allowed to fine manufacturers who don’t provide 
information about their price increases.213 However, outside of this 
Vermont law, when it comes to price increases of existing drugs, there is 
little transparency about how drug manufacturers implement new 
prices.214 
To address the issue of transparency and expand the federal 
government’s negotiation power for both Medicaid and Medicare Part D, 
an evaluation process should be instituted, like that in Sweden and France. 
Both of these countries evaluate a drug by analyzing its therapeutic value, 
comparing them to existing drugs, and/or looking at research and 
development costs. The government, negotiating for Medicaid and 
Medicare Part D, should also look at these factors by requiring 
participating drug manufacturers to disclose such information to them 
when seeking to be covered by these plans. For example, if a drug offers 
a high therapeutic value, an increase in the drug rebate should be obtained 
so that patients are able to have access to these medications at a lower 
price. At the same time, research and development would also be factored 
into the rebate paid by companies. By factoring in the cost of research and 
development of a new medicine, drug manufacturers who spend a large 
amount of money on research and development and create innovative 
medicines with a high therapeutic value would pay a lower rebate 
percentage. Factoring in the cost of research and development would also 
address the argument that negotiating drugs impedes the creation of new 
medicines by discouraging research and development.215 By rewarding 
                                                                                                             
210 Peter Loftus, Drug Pricing Report Shows Limits of Transparency Push, WALL ST. J. 
(Dec. 31, 2016, 9:00 AM), https://www.wsj.com/articles/drug-pricing-report-shows-
limits-of-transparency-push-1483192856. 
211 Id. 
212 Id. 
213 Id. 
214 See id. 
215 See Rachel Becker, If you live in the US, you pay too much for prescription drugs, 
THE VERGE (Aug. 23, 2016, 7:01 PM), http://www.theverge.com/2016/8/23/12616730/
prescription-drug-prices-american-healthcare-cost. 
2017] UNIVERSITY OF MIAMI BUSINESS LAW REVIEW 157 
 
drug manufacturers with a lower rebate amount, this increased negotiating 
power of the government would likely not get in the way of the creation 
of new, innovating drugs. 
In addition, following the evaluation process, the government should 
use a reassessment standard, such as the kind seen in France. In France, 
following a certain time period after drug prices are set, manufacturers are 
sometimes required to produce additional cost–effectiveness data.216 The 
Transparency Committee uses this data to reassess the drug, which can 
impact its price and the rebate the manufacturer obtains.217 The United 
States should implement a similar reassessment standard for drugs after 
the government’s original negotiations for Medicaid and Medicare Part D. 
Currently, under Medicaid, a drug manufacturer has to pay a higher 
rebate if the price of their drug rises faster than general inflation.218 
Although this is a useful way to reprimand drug manufacturers for 
increasing the price of their drugs, a reassessment standard can be a better 
way to hold manufacturers more accountable for price increases. A 
reassessment would be limited to those drug manufacturers whose 
products have seen high price increases following the initial negotiations. 
Under this reassessment standard, the United States would require these 
drug manufacturers to justify why they raise the price of their medicines 
and explain how they come up with the new price. Based on the 
information received by drug manufacturers, the government would then 
determine how much of a higher rebate amount the manufacturer should 
pay for its price increase. At the same time, the information received by 
manufacturers would have a positive effect on the public’s discussion of 
drug price increases. 
As stated in this Comment, drug manufacturers have been guarded 
about why they increase the price of their drugs. By requiring these 
manufacturers to release that information once they have implemented a 
high price increase, the public would finally know their reasoning behind 
these increases. This can also lead to a more thoughtful dialogue between 
manufacturers and the public than the kind seen in the past, such as at 
congressional hearings. Furthermore, a reassessment might act as a 
deterrence by making drug manufacturers hesitant about raising prices, 
since manufacturers will know that they will be required to disclose 
reassessment data once their drugs have reached a high price. 
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V. CONCLUSION 
When it comes to increasing prescription drug prices, there is a great 
need for reform in the pharmaceutical industry. However, there is no 
perfect fix. A solution requires carefully evaluating all of the players 
affecting the cost of drugs, while keeping in mind that the United States 
has a healthcare system that is different from those seen in other countries 
around the world. Furthermore, reform should strike a delicate balance of 
pleasing both the public and drug manufacturers. One such solution to high 
drug prices is a system that sets a price ceiling for off–patent medications, 
increases the negotiation power of the U.S. government by allowing the 
government to negotiate for Medicare Part D beneficiaries, and requires 
greater transparency when manufacturers seek to have their drugs covered 
under Medicaid and Medicare Part D. Although this will not completely 
alleviate the problem of drug price increases, it is a step in the right 
direction and will likely result in lower drug prices. By increasing the price 
of their drugs, pharmaceutical companies have directly impacted the 
ability of consumers to access drugs and have forced them to seek out 
alternatives. Ultimately, the United States government must recognize this 
widespread problem and prioritize the livelihood of Americans across the 
country. 
